Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431712 | 0.82 | MAPT (0.53) | KDM4EALDH1A1TSHRLMNAHTT | |
| SCHEMBL14289544 | 0.72 | TRPV1 (0.74) | TRPV1 | |
| SCHEMBL3118539 | 0.68 | TRPV1 (0.55) | PIP4K2ATRPV1 | |
| SCHEMBL5470970 | 0.67 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL5486026 | 0.66 | MAPT (0.57) | KDM4EALDH1A1TSHRLMNAHTT | |
| SCHEMBL4148677 | 0.65 | TRPV1 (0.54) | TRPV1 | |
| SCHEMBL2848807 | 0.64 | TRPV1 (0.66) | TRPV1 | |
| SCHEMBL4867914 | 0.64 | TRPV1 (0.66) | TRPV1 | |
| SCHEMBL14289543 | 0.63 | TRPV1 (0.80) | PIP4K2ATRPV1 | |
| SCHEMBL14289488 | 0.63 | TRPV1 (0.73) | PIP4K2ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| EP-1720877-A2 | ARYL SUBSTITUTED PURINE ANALOGUES | Neurogen Corporation (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005084401-A2 | ARYL SUBSTITUTED PURINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197559-A1 | Aryl substituted purine analogues | ADORA2A, GART, P2RX7 | KDM4E 3890/4885ALDH1A1 569/4885TSHR 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.